glp 1 news Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease News Brief: FDA Seeks Removal

was an associate editor of Alzheimers Research & Therapy in 2020/2021 and is an associate editor at Brain

In the multiple ascending dose study, participants receiving the highest dose level of 48 mg achieved a striking mean body-weight reduction of 9.1% by Day 54, with weight loss trends showing no signs of plateauing

And they can achieve a slow, gradual weight loss, usually over the course of two years, potentially more, and then be seen for weight maintenance

Should you consider Rapamycin

While this has not been observed in humans at standard doses, and microdoses are far below standard doses, patients with existing thyroid conditions (including Hashimoto) should have regular thyroid monitoring

This issue has never happened before, and Ive been using the app since May 2025